Table 3 Bivariate Cox regression analysis

From: Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases

 

HR

95% Confidence interval

p value

Age

1.008

1.002–1.014

0.005

Gender

0.970

0.848–1.109

0.654

BMI

0.968

0.955–0.982

<0.001

Race

  White

Reference

  

  Black

0.903

0.634–1.287

0.573

  Asian

1.533

0.885–2.656

0.128

  Other

0.867

0.562–1.339

0.521

 Additional comorbidities

1.134

0.992–1.298

0.066

 Location skeleton

1.171

1.023–1.340

0.022

Primary tumor

  Category 1 (slow growth)

Reference

  

  Category 2 (moderate growth)

1.566

1.316–1.863

<0.001

  Category 3 (rapid growth)

3.071

2.603–3.624

<0.001

 Other bone metastases

1.255

1.088–1.449

0.002

 Visceral metastases

1.975

1.723–2.266

<0.001

 Previous local radiation

1.121

0.965–1.303

0.136

 Previous systemic therapy

1.508

1.310–1.736

<0.001

 Hemoglobin

0.875

0.839–0.913

<0.001

 NLR (4.7)

1.594

1.384–1.836

<0.001

 NLR (5.0)

1.558

1.356–1.791

<0.001

 NLR (4.0)

1.545

1.329–1.795

<0.001

 NLR (3.0)

1.579

1.320–1.890

<0.001

 PLR (408)

1.747

1.512–2.018

<0.001

 PLR (150)

1.339

1.120–1.601

0.001

 PLR (300)

1.391

1.215–1.592

<0.001

  1. NLR neutrophil-to-lymphocyte ratio, PLR  platelet-to-lymphocyte ratio
Back to article page